MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical OfficerPRNewsWire · Oct 13, 2026
MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference ReductionPRNewsWire · Sep 9, 2026
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire · Aug 6, 2026Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.82 | -$0.90 | Miss |
| May 14, 2026 | -$0.76 | -$0.79 | Miss |
| Mar 26, 2026 | -$2.06 | $1.01 | Beat |
| Nov 6, 2025 | -$2.86 | -$1.54 | Beat |
| Aug 7, 2025 | -$3.52 | -$2.86 | Beat |
| May 14, 2025 | -$6.27 | -$3.96 | Beat |